Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06623786

Cancer Patient Remote Monitoring for Timely Communication Study

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Asklepios proresearch · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is designed as a prospective, single-arm observational, mixed-method study. Patients with stage IV NSCLC or inoperable mesothelioma will be included and will be treated with immunotherapy according to current guidelines and standard of care. Patients may receive either a PD1/L1 inhibitor monotherapy or, if indicated, together with a CTLA4 inhibitor. Immunotherapy may be administered alone or together with chemotherapy as per site standard/physician's choice. Patients will be given access to a mobile app. Patients will receive daily questions via the app to assess immune-related adverse events between clinic visits and their well-being.

Conditions

Timeline

Start date
2024-10-01
Primary completion
2026-04-01
Completion
2026-04-01
First posted
2024-10-02
Last updated
2024-10-02

Source: ClinicalTrials.gov record NCT06623786. Inclusion in this directory is not an endorsement.